AP9901631A0 - Reverse hydroxamate derivatives as metalloprotease inhibitors. - Google Patents

Reverse hydroxamate derivatives as metalloprotease inhibitors.

Info

Publication number: AP9901631A0
Authority: AP; ARIPO
Prior art keywords: butyl; ethyl; hydrogen; tnf; sec
Prior art date: 1997-02-26

Application number

APAP/P/1999/001631A

Other languages

English (en)

Inventor

Marc W Andersen

Darryl Lynn Mcdougald

David Lee Musso

Michael Howard Rabinowitz

Jennifer Badiang Stanford

Robert William Wiethe

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-26

Filing date

1998-02-24

Publication date

1999-09-30

1998-02-24 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

1999-09-30 Publication of AP9901631A0 publication Critical patent/AP9901631A0/en

Links

239000003475 metalloproteinase inhibitor Substances 0.000 title 1
-1 3,3,3-trifluoro-n-propyl Chemical group 0.000 abstract 4
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
150000001875 compounds Chemical class 0.000 abstract 2
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 2
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
102000005741 Metalloproteases Human genes 0.000 abstract 1
108010006035 Metalloproteases Proteins 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000000217 alkyl group Chemical group 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
230000003389 potentiating effect Effects 0.000 abstract 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- C07D285/135—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyridine Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Detergent Compositions (AREA)
Thiazole And Isothizaole Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

APAP/P/1999/001631A 1997-02-26 1998-02-24 Reverse hydroxamate derivatives as metalloprotease inhibitors. AP9901631A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3911297P	1997-02-26	1997-02-26
PCT/EP1998/001015 WO1998038179A1 (en)	1997-02-26	1998-02-24	Reverse hydroxamate derivatives as metalloprotease inhibitors

Publications (1)

Publication Number	Publication Date
AP9901631A0 true AP9901631A0 (en)	1999-09-30

Family

ID=21903750

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/1999/001631A AP9901631A0 (en)	1997-02-26	1998-02-24	Reverse hydroxamate derivatives as metalloprotease inhibitors.

Country Status (16)

Country	Link
EP (1)	EP1019386A1 (is)
JP (1)	JP2001513767A (is)
KR (1)	KR20000075681A (is)
AP (1)	AP9901631A0 (is)
AR (1)	AR013070A1 (is)
AU (1)	AU6822398A (is)
BR (1)	BR9807763A (is)
CA (1)	CA2281664A1 (is)
HR (1)	HRP980096A2 (is)
IS (1)	IS5159A (is)
NO (1)	NO994103L (is)
PE (1)	PE59199A1 (is)
PL (1)	PL335378A1 (is)
TR (1)	TR199902063T2 (is)
WO (1)	WO1998038179A1 (is)
ZA (1)	ZA981532B (is)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6294573B1 (en)	1997-08-06	2001-09-25	Abbott Laboratories	Reverse hydroxamate inhibitors of matrix metalloproteinases
US6235786B1 (en)	1997-08-06	2001-05-22	Abbott Laboratories	Reverse hydroxamate inhibitors of matrix metalloproteinases
EP1052984B1 (en)	1998-02-07	2004-05-12	Vernalis (Oxford) Ltd	Antibacterial agents
GB9818621D0 (en) *	1998-08-26	1998-10-21	Glaxo Group Ltd	Formamide compounds as therapeutic agents
AU5688999A (en) *	1998-08-26	2000-03-21	Glaxo Group Limited	Formamide compounds as therapeutic agents
EP1121118A4 (en) *	1998-08-26	2002-09-11	Glaxo Group Ltd	FORMAMIDE-BASED THERAPEUTIC AGENTS
US6288261B1 (en)	1998-12-18	2001-09-11	Abbott Laboratories	Inhibitors of matrix metalloproteinases
US6329550B1 (en)	1998-12-31	2001-12-11	Aventis Pharmaceuticals Inc.	Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
GB9918869D0 (en) *	1999-08-10	1999-10-13	British Biotech Pharm	Antibacterial agents
JP2003081838A (ja) *	2001-09-11	2003-03-19	Rohto Pharmaceut Co Ltd	グルコサミン製剤
PE20030701A1 (es)	2001-12-20	2003-08-21	Schering Corp	Compuestos para el tratamiento de trastornos inflamatorios
EP2042181A1 (en)	2002-02-04	2009-04-01	ALFAMA-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda.	Use of co-releasing compounds for the manufacture of a medicament for the treatment of inflammatory diseases
WO2004071384A2 (en) *	2003-02-11	2004-08-26	Boehringer Ingelheim International Gmbh	New pharmaceutical compositions based on anticholinergics and tace-inhibitors
WO2007092899A2 (en) *	2006-02-09	2007-08-16	The Burnham Institute	Inhibitors of membrane type-1 matrix metalloproteinase for the treatment of insulin-dependent diabetes mellitus
US20110015158A1 (en)	2007-12-11	2011-01-20	Viamet Pharmaceuticals, Inc.	Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US8232290B2 (en)	2008-03-25	2012-07-31	Affectis Pharmaceuticals Ag	P2X7R antagonists and their use
EP2243772B1 (en)	2009-04-14	2012-01-18	Affectis Pharmaceuticals AG	Novel P2X7R antagonists and their use
WO2012110190A1 (en)	2011-02-17	2012-08-23	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
US9163044B2 (en)	2011-04-19	2015-10-20	Alfama, Inc.	Carbon monoxide releasing molecules and uses thereof
WO2012163456A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
WO2012163792A1 (en)	2011-05-27	2012-12-06	Affectis Pharmaceuticals Ag	Novel p2x7r antagonists and their use
JP6134710B2 (ja)	2011-07-21	2017-05-24	アルファーマインコーポレイテッドＡｌｆａｍａ，Ｉｎｃ．	一酸化ルテニウム放出分子およびその使用
AU2019352741A1 (en)	2018-10-04	2021-05-06	Assistance Publique-Hôpitaux De Paris (Aphp)	EGFR inhibitors for treating keratodermas

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9223904D0 (en) *	1992-11-13	1993-01-06	British Bio Technology	Inhibition of cytokine production
US6037472A (en) *	1993-11-04	2000-03-14	Syntex (U.S.A.) Inc.	Matrix metalloprotease inhibitors
PT822186E (pt) *	1994-01-20	2000-08-31	British Biotech Pharm	L-tert-leucina-2-piridilamida
GB9514867D0 (en) *	1995-07-20	1995-09-20	British Biotech Pharm	Metalloproteinase inhibitors
CZ292617B6 (cs) *	1995-11-23	2003-11-12	British Biotech Pharmaceuticals Limited	Inhibitory metaloproteinázy a farmaceutický prostředek

1998
- 1998-02-24 CA CA002281664A patent/CA2281664A1/en not_active Abandoned
- 1998-02-24 PL PL98335378A patent/PL335378A1/xx unknown
- 1998-02-24 AP APAP/P/1999/001631A patent/AP9901631A0/en unknown
- 1998-02-24 HR HR60/039,112A patent/HRP980096A2/hr not_active Application Discontinuation
- 1998-02-24 KR KR1019997007747A patent/KR20000075681A/ko not_active Withdrawn
- 1998-02-24 WO PCT/EP1998/001015 patent/WO1998038179A1/en not_active Ceased
- 1998-02-24 ZA ZA9801532A patent/ZA981532B/xx unknown
- 1998-02-24 TR TR1999/02063T patent/TR199902063T2/xx unknown
- 1998-02-24 AU AU68223/98A patent/AU6822398A/en not_active Abandoned
- 1998-02-24 BR BR9807763-5A patent/BR9807763A/pt not_active Application Discontinuation
- 1998-02-24 JP JP53728498A patent/JP2001513767A/ja active Pending
- 1998-02-24 EP EP98913575A patent/EP1019386A1/en not_active Withdrawn
- 1998-02-25 PE PE1998000138A patent/PE59199A1/es not_active Application Discontinuation
- 1998-02-25 AR ARP980100842A patent/AR013070A1/es unknown
1999
- 1999-08-20 IS IS5159A patent/IS5159A/is unknown
- 1999-08-25 NO NO994103A patent/NO994103L/no unknown

Also Published As

Publication number	Publication date
NO994103L (no)	1999-10-25
KR20000075681A (ko)	2000-12-26
JP2001513767A (ja)	2001-09-04
IS5159A (is)	1999-08-20
BR9807763A (pt)	2000-02-22
ZA981532B (en)	1999-08-24
EP1019386A1 (en)	2000-07-19
PE59199A1 (es)	1999-06-24
AU6822398A (en)	1998-09-18
NO994103D0 (no)	1999-08-25
WO1998038179A1 (en)	1998-09-03
TR199902063T2 (xx)	1999-12-21
AR013070A1 (es)	2000-12-13
PL335378A1 (en)	2000-04-25
CA2281664A1 (en)	1998-09-03
HRP980096A2 (en)	1998-12-31

Publication	Publication Date	Title
AP9901631A0 (en)	1999-09-30	Reverse hydroxamate derivatives as metalloprotease inhibitors.
AU2910600A (en)	2000-08-29	Phenyl urea and phenyl thiourea derivatives
MY131271A (en)	2007-07-31	Liquid detergents with an aryl boronic acid for inhibition of proteolytic enzyme
DK1052984T3 (da)	2004-09-20	Antibakterielle midler
NZ509239A (en)	2002-10-25	2-(4-(N-salicyloyl)aminophenyl)propionic acid useful as a carrier in compositions for delivering active agents
AU7517400A (en)	2001-04-24	N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
TW238312B (is)	1995-01-11
AU5875498A (en)	1998-08-25	Substituted derivatives of benzosulphonamides as inhibitors of the enzyme cyclo oxygenase ii
BG105027A (en)	2001-11-30	Herbicidal mixture containing a 3 heterocyclyl-substituted benzoyl derivative
MX9800718A (es)	1998-04-30	Derivados de 2-(4-substituidos)-bencilamino-2-metil- propanamida.
CA2129013A1 (en)	1993-07-29	Pyridinecarboximidamide compounds and the use thereof
WO2002028844A1 (en)	2002-04-11	Thiazole or oxazole derivatives
AU9066498A (en)	1999-02-16	Substituted 6-alkylphenanthridines
SI1450750T1 (sl)	2010-02-26	Derivati 2-amino-4-piridilmetil-tiazolina in njihova uporaba kot inhibitorji inducibilne NO-sintaze
NO983283L (no)	1998-09-16	Hydrokamsyre-baserte Kollagenase-inhibitorer
DE69405760D1 (de)	1997-10-23	4-aza-pregnan-5-alpha-reductase isozym 1 inhibitoren
EP0516860A4 (en)	1993-12-01	Chromone derivative and aldose reductase inhibitor containing the same as active ingredient
NO20005391L (no)	2000-12-19	Nye oktahydro-6,10-diokso-6H-pyridazino[1,2-a][1,2]diazepin-1- karboksylsyrederivater metyl, etyl, propyl, isopropyl, n-butyl, isobutyl eller terbutyl, eller benzyl eller naftyl
MX9709340A (es)	1998-02-28	Inhibidores de proteasa de serina derivados de imidazo (1,5a) piridina.
MXPA05000517A (es)	2005-03-23	Derivados de sulfonilpiperidina que contienen una porcion alquenilo o alquinilo para uso como inhibidores de metaloproteinasas de matriz.
WO2001077095A3 (en)	2002-06-27	Derivatives of alpha-mercaptoacetamide
HK1030955A (en)	2001-05-25	Thiadiazole compounds useful as inhibitors of cysteine activity dependent enzymes
JPS5758654A (en)	1982-04-08	Germanium compound of prolylaminoacid derivative and its preparation